SCHEMBL30213765

SCHEMBL30213765

Fc1ccc(Nc2ccnc(OCCN3CCOCC3)n2)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 14/20 0.54
▸ ERBB2 P04626 4/20 0.49
▸ PRKD3 O94806 2/20 0.49
▸ SRC P12931 2/20 0.49
▸ PRKD1 Q15139 2/20 0.49
▸ MAPK14 Q16539 2/20 0.49
▸ BRAF P15056 2/20 0.49
▸ KDR P35968 2/20 0.49
▸ CIT O14578 1/20 0.49
▸ GAK O14976 1/20 0.49
▸ EPHB6 O15197 1/20 0.49
▸ ABCC4 O15439 1/20 0.49
▸ DAPK3 O43293 1/20 0.49
▸ RIPK2 O43353 1/20 0.49
▸ NR1I2 O75469 1/20 0.49
▸ RPS6KA4 O75676 1/20 0.49
▸ STK17B O94768 1/20 0.49
▸ STK10 O94804 1/20 0.49
▸ ABCB11 O95342 1/20 0.49
▸ MAP4K4 O95819 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30213670 0.95 EGFR (0.54) EGFRERBB2PRKD3SRCPRKD1
SCHEMBL28540768 0.89 EGFR (0.54) EGFRERBB2AXLERBB4MAP3K8
SCHEMBL30213684 0.89 EGFR (0.54) EGFRERBB2AXLERBB4MAP3K8
SCHEMBL30213663 0.83 EGFR (0.61) EGFRERBB2
SCHEMBL30213858 0.81 EGFR (0.49) EGFRERBB2PRKD3SRCPRKD1
SCHEMBL30213748 0.81 EGFR (0.62) EGFRERBB2KCNH2
SCHEMBL30213751 0.80 EGFR (0.49) EGFRERBB2PRKD3SRCPRKD1
SCHEMBL30213768 0.80 EGFR (0.51) EGFRERBB2ERBB3SLC6A3KCNH2
SCHEMBL8317480 0.79 EGFR (0.66) EGFRERBB2PRKD3SRCPRKD1
SCHEMBL30213666 0.78 EGFR (0.66) EGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112574177-B Pyrimidine derivatives and application thereof in preparing antitumor drugs 陕西师范大学 2023-01-31 — — CN disclosed
Send feedback